Overview

Influence of Glitazones on the Vasodilatory Effect of High-density Lipoprotein (HDL) Lipoproteins

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
HDL from patients with type 2 diabetes show a significant reduction of their endothelium-dependent vasodilatory effect. The primary objective of the study is to analyze whether treatment with glitazones (pioglitazone and rosiglitazone)may improve the endothelium-dependent vasodilatory effect of HDL lipoproteins in patients with type 2 diabetes. The secondary objectives are: - to analyze the effect of glitazone treatment on phospholipase A2 - to look for possible differences between the effects of pioglitazone and those of rosiglitazone - to analyze the glycemic response to glitazone therapy according to clinical and biological baseline characteristics.
Phase:
Phase 4
Details
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Treatments:
Pioglitazone
Rosiglitazone